FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000259493> ?p ?o ?g. }

• W2000259493 endingPage "1671" @default.
• W2000259493 startingPage "1659" @default.
• W2000259493 abstract "Although extracellular nucleotides have been shown to confer mitogenic effects in cultured rat mesangial cells through activation of purinergic P2 receptors (P2Y receptors), thus far the in vivo relevance of these findings is unclear. Virtually all cells and in particular the dense granules of platelets contain high levels of nucleotides that are released upon cell injury or platelet aggregation. In experimental mesangial proliferative glomerulonephritis in the rat (anti-Thy1 model), mesangiolysis and glomerular platelet aggregation are followed by a pronounced mesangial cell (MC) proliferative response leading to glomerular hypercellularity. Therefore, we examined the role of extracellular nucleotides and their corresponding receptors in nucleotide-stimulated cultured mesangial cells and in inflammatory glomerular disease using the P2 receptor antagonist PPADS.The effects of PPADS on nucleotide- or fetal calf serum (FCS)-stimulated proliferation of cultured MC were measured by cell counting and [3H]thymidine incorporation assay. After induction of the anti-Thy1 model, rats received injections of the P2-receptor antagonist PPADS at different doses (15, 30, 60 mg/kg BW). Proliferating mesangial and non-mesangial cells, mesangial cell activation, matrix accumulation, influx of inflammatory cells, mesangiolysis, microaneurysm formation, and renal functional parameters were assessed during anti-Thy1 disease. P2Y-mRNA and protein expression was assessed using RT-PCR and real time PCR, Northern blot analysis, in situ hybridization, and immunohistochemistry.In cultured mesangial cells, PPADS inhibited nucleotide, but not FCS-stimulated proliferation in a dose-dependent manner. In the anti-Thy1 model, PPADS specifically and dose-dependently reduced early (day 3), but not late (day 8), glomerular mesangial cell proliferation as well as phenotypic activation of the mesangium and slightly matrix expansion. While no consistent effect was obtained in regard to the degree of mesangiolysis, influx of inflammatory cells, proteinuria or blood pressure, PPADS treatment increased serum creatinine and urea in anti-Thy1 rats. P2Y receptor expression (P2Y2 and P2Y6) was detected in cultured MC and isolated glomeruli, and demonstrated a transient marked increase during anti-Thy1 disease.These data strongly suggest an in vivo role for extracellular nucleotides in mediating early MC proliferation after MC injury." @default.
• W2000259493 created "2016-06-24" @default.
• W2000259493 creator A5016795540 @default.
• W2000259493 creator A5019508817 @default.
• W2000259493 creator A5029033280 @default.
• W2000259493 creator A5030537260 @default.
• W2000259493 creator A5040186076 @default.
• W2000259493 creator A5080306130 @default.
• W2000259493 date "2002-11-01" @default.
• W2000259493 modified "2023-10-06" @default.
• W2000259493 title "P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangial proliferative glomerulonephritis" @default.
• W2000259493 cites W1607766476 @default.
• W2000259493 cites W1815757713 @default.
• W2000259493 cites W1840837207 @default.
• W2000259493 cites W1947888345 @default.
• W2000259493 cites W1963725827 @default.
• W2000259493 cites W1977199922 @default.
• W2000259493 cites W1977702903 @default.
• W2000259493 cites W1981183509 @default.
• W2000259493 cites W1991433173 @default.
• W2000259493 cites W1992030944 @default.
• W2000259493 cites W1997080687 @default.
• W2000259493 cites W1998156838 @default.
• W2000259493 cites W2004008970 @default.
• W2000259493 cites W2004516283 @default.
• W2000259493 cites W2007913522 @default.
• W2000259493 cites W2008808395 @default.
• W2000259493 cites W2022700706 @default.
• W2000259493 cites W2024459956 @default.
• W2000259493 cites W2028606370 @default.
• W2000259493 cites W2033465719 @default.
• W2000259493 cites W2055808642 @default.
• W2000259493 cites W2057216006 @default.
• W2000259493 cites W2060300730 @default.
• W2000259493 cites W2061348306 @default.
• W2000259493 cites W2063669495 @default.
• W2000259493 cites W2066679122 @default.
• W2000259493 cites W2086795928 @default.
• W2000259493 cites W2095695875 @default.
• W2000259493 cites W2144373920 @default.
• W2000259493 cites W2150062642 @default.
• W2000259493 cites W2338002631 @default.
• W2000259493 cites W4294216491 @default.
• W2000259493 doi "https://doi.org/10.1046/j.1523-1755.2002.00621.x" @default.
• W2000259493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12371966" @default.
• W2000259493 hasPublicationYear "2002" @default.
• W2000259493 type Work @default.
• W2000259493 sameAs 2000259493 @default.
• W2000259493 citedByCount "29" @default.
• W2000259493 countsByYear W20002594932012 @default.
• W2000259493 countsByYear W20002594932013 @default.
• W2000259493 countsByYear W20002594932015 @default.
• W2000259493 countsByYear W20002594932018 @default.
• W2000259493 countsByYear W20002594932020 @default.
• W2000259493 crossrefType "journal-article" @default.
• W2000259493 hasAuthorship W2000259493A5016795540 @default.
• W2000259493 hasAuthorship W2000259493A5019508817 @default.
• W2000259493 hasAuthorship W2000259493A5029033280 @default.
• W2000259493 hasAuthorship W2000259493A5030537260 @default.
• W2000259493 hasAuthorship W2000259493A5040186076 @default.
• W2000259493 hasAuthorship W2000259493A5080306130 @default.
• W2000259493 hasBestOaLocation W20002594931 @default.
• W2000259493 hasConcept C126322002 @default.
• W2000259493 hasConcept C134018914 @default.
• W2000259493 hasConcept C160225129 @default.
• W2000259493 hasConcept C170493617 @default.
• W2000259493 hasConcept C2779131090 @default.
• W2000259493 hasConcept C2780019924 @default.
• W2000259493 hasConcept C2780091579 @default.
• W2000259493 hasConcept C2780368995 @default.
• W2000259493 hasConcept C2780410667 @default.
• W2000259493 hasConcept C2780688133 @default.
• W2000259493 hasConcept C3018920779 @default.
• W2000259493 hasConcept C55493867 @default.
• W2000259493 hasConcept C57306754 @default.
• W2000259493 hasConcept C62112901 @default.
• W2000259493 hasConcept C71924100 @default.
• W2000259493 hasConcept C86803240 @default.
• W2000259493 hasConceptScore W2000259493C126322002 @default.
• W2000259493 hasConceptScore W2000259493C134018914 @default.
• W2000259493 hasConceptScore W2000259493C160225129 @default.
• W2000259493 hasConceptScore W2000259493C170493617 @default.
• W2000259493 hasConceptScore W2000259493C2779131090 @default.
• W2000259493 hasConceptScore W2000259493C2780019924 @default.
• W2000259493 hasConceptScore W2000259493C2780091579 @default.
• W2000259493 hasConceptScore W2000259493C2780368995 @default.
• W2000259493 hasConceptScore W2000259493C2780410667 @default.
• W2000259493 hasConceptScore W2000259493C2780688133 @default.
• W2000259493 hasConceptScore W2000259493C3018920779 @default.
• W2000259493 hasConceptScore W2000259493C55493867 @default.
• W2000259493 hasConceptScore W2000259493C57306754 @default.
• W2000259493 hasConceptScore W2000259493C62112901 @default.
• W2000259493 hasConceptScore W2000259493C71924100 @default.
• W2000259493 hasConceptScore W2000259493C86803240 @default.
• W2000259493 hasIssue "5" @default.
• W2000259493 hasLocation W20002594931 @default.
• W2000259493 hasLocation W20002594932 @default.
• W2000259493 hasOpenAccess W2000259493 @default.

• next